NAA Services for Anti-GMCSF
Possessing world-leading technology platforms and professional scientific staff, Creative Biolabs is always dedicated to assisting our clients with the most satisfactory scientific research services. In terms of NAA (natural autoantibodies) research, we can provide a full range of anti-GMCSF marker products and customized services for our worldwide customers with years of experience and high-end technologies.
Background of Anti-GMCSF
Granulocyte-macrophage colony-stimulating factor (GMCSF), also known as colony-stimulating factor 2, is a critical hematopoietic growth factor and immune modulator. This heavily glycosylated cytokine was firstly purified and reported in 1977 from lung tissue-conditioned medium of a lipopolysaccharide-induced mouse. GMCSF is a kind of monomeric glycoprotein produced by endothelial cells, monocytes, macrophages, mast cells, natural killer cells, fibroblasts and T cells in response to inflammatory mediators as a cytokine. GMCSF is an important part of the immune system and inflammatory response because it can stimulate the production of granulocytes and monocytes, while regulating functional activities in mature cells of the immune system.
Anti-GMCSF antibody is an autoantibody against GMCSF or cytokine antibody that neutralizes the biologic activity of GMCSF. GMCSF autoantibody has been frequently reported both in healthy individuals and in patients with autoimmune, especially autoimmune pulmonary alveolar proteinosis.
Fig.1 Cell types that produce and respond to GMCSF. (Palle, 2017)
The Role of Anti-GMCSF in Pulmonary Alveolar Proteinosis (PAP)
Pulmonary alveolar proteinosis (PAP) is a rare respiratory disorder characterized by abnormal accumulation of surfactant-derived lipoprotein compounds within the alveoli and terminal airways, causing dyspnea and susceptibility to pulmonary infection. The abnormal accumulation of surfactant material usually results from defective surfactant regulation and clearance by alveolar macrophages. Animal models, scientific researches and clinical tests indicate that high titer of GMCSF autoantibody in blood and tissues, particularly in pulmonary alveoli, is specifically associated with PAP.
Anti-GMCSF autoantibody or homozygous deletion of GMCSF genes causes PAP mainly by neutralizing GMCSF biological activity and inducing a range of disorders in alveolar macrophage function including impaired chemotaxis, adhesion, phagocytosis, microbicidal activity, etc. Anti-GMCSF is able to serve as an indicator or biomarker to reflect the severity in patients with PAP.
Fig.2 Examples of how cytokine antibodies fit into hematopoiesis and host defense in the context of hematopoiesis and normal functions. (Watanabe, 2010)
Features of Our Services About NAA
- Comprehensive NAA services including NAA detection, NAA profiling, and custom NAA products
- Specialized scientists for antibodies and NAA
- Abundant experience in NAA and related projects
- Well-established and powerful technology platforms
- High efficiency and best after-sale services
Creative Biolabs has devoted to the investigations and applications of NAA many years, and anti-GMCSF is just one representative autoantibody we have researched. If you are interested in NAA research, please feel free to contact us for more detailed information. Our optimized technology platforms and scientists are able to offer the largest and diversiform portfolio of NAA products, related applications and custom services based on the requirements of the clients, which can help you get satisfactory results without repeated trials and a milestone development in your NAA research.
References:
- Palle, P.; et al. Cytokine Signaling in Multiple Sclerosis and Its Therapeutic Applications. Medical Sciences (Basel, Switzerland). 2017, 5(4): 23.
- Watanabe, M.; et al. High avidity cytokine autoantibodies in health and disease: pathogenesis and mechanisms. Cytokine & Growth Factor Reviews. 2010, 21(4): 263-273.